Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

13 matching registry records; showing 13 on this page, newest registry updates first. Search checked 2026-11-08 17:42 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2 / Phase 3RecruitingINTERVENTIONAL

Thymosin-α1 for Recurrent Implantation Failure

ClinicalTrials.gov · NCT07675980 · Registry updated: 2026-10-15

Condition / research focus: Recurrent Implantation Faliure
Sponsor: Fakih IVF Fertility Center
Countries with listed sites: United Arab Emirates
Registry dates and results: Start: 2026-02-11. Completion: 2027-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin Alpha1 (drug)
Placebo Control (other)

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Fakih IVF
Abu Dhabi, United Arab Emirates
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Protective Effect of Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)

ClinicalTrials.gov · NCT05339529 · Registry updated: 2026-09-14

Condition / research focus: Acute Aortic Syndrome; Aortic Dissection Type A
Sponsor: Nanjing Medical University
Countries with listed sites: China
Registry dates and results: Start: 2022-07-01. Completion: 2026-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin Alpha1, 28A-Glycine-28B-L-Arginine-28C-L-Glutamic Acid-28D-L-Alanine-28E-L-Proline-28F-L-Alanine-28G-L-Asparagine- (drug)
Blank control (drug)

Where the study takes place — 15 listed sites

The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China
Site recruitment: Not reported
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Site recruitment: Not reported
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Site recruitment: Not reported
Nanjing First Hospital Nanjing Medical University
Nanjing, Jiangsu, China
Site recruitment: Not reported
Subei People's Hospital of Jiangsu Province
Yangzhou, Jiangsu, China
Site recruitment: Not reported
Qilu Hospital of Shandong University
Jinan, Shandong, China
Site recruitment: Not reported
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Site recruitment: Not reported
The Friendship Hospital of Yili Kazak Autonomous Prefecture
Kazak, Xinjiang, China
Site recruitment: Not reported
The Seventh Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
Site recruitment: Not reported
The First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
Site recruitment: Not reported
Beijing Anzhen Hospital Capital Medical University
Beijing, China
Site recruitment: Not reported
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, China
Site recruitment: Not reported
The Second Affiliated Hospital of Nanchang University
Nanchang, China
Site recruitment: Not reported
Shanghai East Hospital Tongji University
Shanghai, China
Site recruitment: Not reported
TEDA International Cardiovascular Hospital
Tianjin, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

ClinicalTrials.gov · NCT06139419 · Registry updated: 2026-08-03

Condition / research focus: Non-small Cell Lung Cancer
Sponsor: Sun Yat-sen University
Countries with listed sites: China
Registry dates and results: Start: 2023-07-25. Completion: 2026-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

definitive radiotherapy (radiation)
induction chemo-immunotherapy (drug) — also listed as: albumin-bound paclitaxel, cisplatin, tislelizumab
concurrent chemotherapy (drug) — also listed as: albumin-bound paclitaxel, cisplatin
Immunotheapy consolidation (drug) — also listed as: tislelizumab
Thymosin Alpha1 (drug) — also listed as: thymalfasin

Where the study takes place — 1 listed sites

Sun yat-sen university cancer center
Guangzhou, Guangdong, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableEnrolling by invitationINTERVENTIONAL

Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI)

ClinicalTrials.gov · NCT06966687 · Registry updated: 2026-01-14

Condition / research focus: Aortic Dissection; Aortic Dissection Aneurysm
Sponsor: Nanjing Medical University
Countries with listed sites: China
Registry dates and results: Start: 2025-04-01. Completion: 2026-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ulinastatin and Thymosin α1 (drug)
Ulinastatin only (drug)

Where the study takes place — 4 listed sites

Beijing Anzhen Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Site recruitment: Not reported
Shanghai East Hospital Tongji University
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
West China Hospital
Chengdu, Sichuan, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC

ClinicalTrials.gov · NCT06607926 · Registry updated: 2024-09-23

Condition / research focus: Resectable Non-Small-Cell Lung Cancer
Sponsor: Xuanwu Hospital, Beijing
Countries with listed sites: China
Registry dates and results: Start: 2024-10-15. Completion: 2025-12-30 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin Alpha 1 (drug) — also listed as: thymalfasin
Tislelizumab (drug)
Platinum-doublet chemotherapy (drug)

Where the study takes place — 1 listed sites

Xuanwu Hospital, Capital Medical University
Beijing, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Early Phase 1CompletedINTERVENTIONAL

Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder

ClinicalTrials.gov · NCT04963712 · Registry updated: 2023-07-18

Condition / research focus: HIV-1-infection
Sponsor: Shanghai Public Health Clinical Center
Countries with listed sites: China
Registry dates and results: Start: 2021-09-01. Completion: 2022-08-11 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Zadaxin (drug) — also listed as: Thymosin α1

Where the study takes place — 1 listed sites

Fudan University
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass

ClinicalTrials.gov · NCT05487469 · Registry updated: 2022-08-04

Condition / research focus: Rheumatic Heart Disease; Cardiopulmonary Bypass; Immunotherapy
Sponsor: Nanjing Medical University
Countries with listed sites: China
Registry dates and results: Start: 2022-07-01. Completion: 2023-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin Alpha1 (drug)
Blank Control (other)

Where the study takes place — 1 listed sites

The first affiliated hospital of nanjing medical university
Nanjing, Jiangsu, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer

ClinicalTrials.gov · NCT03659578 · Registry updated: 2022-01-03

Condition / research focus: Non-small Cell Lung Cancer
Sponsor: Sun Yat-sen University
Countries with listed sites: China
Registry dates and results: Start: 2018-08-09. Completion: 2021-09-30 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Concurrent chemotherapy (drug)
split-course radiotherapy (radiation)
thymosin alpha 1 (drug)

Where the study takes place — 1 listed sites

Sun yat-sen University Cancer Center
Guangzhou, Guangdong, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor

ClinicalTrials.gov · NCT03663764 · Registry updated: 2021-12-10

Condition / research focus: Thymoma and Thymic Carcinoma
Sponsor: Sun Yat-sen University
Countries with listed sites: China
Registry dates and results: Start: 2018-08-13. Completion: 2023-08 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin a1 (drug)
hypofractionated radiotherapy (radiation)
concurrent chemoradiotherapy (drug)

Where the study takes place — 1 listed sites

Sun yat-sen University Cancer Center
Guangzhou, Guangdong, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF

ClinicalTrials.gov · NCT03082885 · Registry updated: 2021-08-16

Condition / research focus: Liver Failure
Sponsor: Sun Yat-sen University
Countries with listed sites: China
Registry dates and results: Start: 2017-04-10. Completion: 2019-07-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin-α1 (drug) — also listed as: Zadaxin

Where the study takes place — 1 listed sites

Third Affliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableNot yet recruitingOBSERVATIONAL

Long-term Prognosis of Patients With Sepsis After Immunotherapy

ClinicalTrials.gov · NCT04901104 · Registry updated: 2021-05-25

Condition / research focus: Long-term Effects of Thymosin Alpha 1 Treatment
Sponsor: Sun Yat-sen University
Countries with listed sites: No country reported
Registry dates and results: Start: 2021-07-01. Completion: 2027-03-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin Alpha1 (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3UnknownINTERVENTIONAL

Thymosin-α1 in Cancer-Related Fatigue

ClinicalTrials.gov · NCT02127268 · Registry updated: 2019-04-10

Condition / research focus: Cancer Related Fatigue; Quality of Life
Sponsor: Zhigang Zhang
Countries with listed sites: China
Registry dates and results: Start: 2014-04. Completion: 2020-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin-α1 (drug)

Where the study takes place — 1 listed sites

Cancer institute
Hangzhou, Zhejiang, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

The Curative Effect of Entecavir Combined Resveratrol on HBV patients-a Multi-center, Random, Open Clinical Trial

ClinicalTrials.gov · NCT03509688 · Registry updated: 2018-04-26

Condition / research focus: Hepatitis
Sponsor: The First Hospital of Jilin University
Countries with listed sites: No country reported
Registry dates and results: Start: 2014-11. Completion: 2017-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

entecavir+resveratrol (drug)
Entecavir (drug)
entecavir+thymosin α1 (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

13 matching registry records; showing 13 on this page, newest registry updates first. Search checked 2026-11-08 17:42 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2 / Phase 3RecruitingINTERVENTIONAL

Thymosin-α1 for Recurrent Implantation Failure

ClinicalTrials.gov · NCT07675980 · Registry updated: 2026-10-15

Condition / research focus: Recurrent Implantation Faliure
Sponsor: Fakih IVF Fertility Center
Countries with listed sites: United Arab Emirates
Registry dates and results: Start: 2026-02-11. Completion: 2027-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin Alpha1 (drug)
Placebo Control (other)

Where the study takes place — 1 listed sites

Fakih IVF
Abu Dhabi, United Arab Emirates
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Protective Effect of Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)

ClinicalTrials.gov · NCT05339529 · Registry updated: 2026-09-14

Condition / research focus: Acute Aortic Syndrome; Aortic Dissection Type A
Sponsor: Nanjing Medical University
Countries with listed sites: China
Registry dates and results: Start: 2022-07-01. Completion: 2026-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin Alpha1, 28A-Glycine-28B-L-Arginine-28C-L-Glutamic Acid-28D-L-Alanine-28E-L-Proline-28F-L-Alanine-28G-L-Asparagine- (drug)
Blank control (drug)

Where the study takes place — 15 listed sites

The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China
Site recruitment: Not reported
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Site recruitment: Not reported
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Site recruitment: Not reported
Nanjing First Hospital Nanjing Medical University
Nanjing, Jiangsu, China
Site recruitment: Not reported
Subei People's Hospital of Jiangsu Province
Yangzhou, Jiangsu, China
Site recruitment: Not reported
Qilu Hospital of Shandong University
Jinan, Shandong, China
Site recruitment: Not reported
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Site recruitment: Not reported
The Friendship Hospital of Yili Kazak Autonomous Prefecture
Kazak, Xinjiang, China
Site recruitment: Not reported
The Seventh Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
Site recruitment: Not reported
The First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
Site recruitment: Not reported
Beijing Anzhen Hospital Capital Medical University
Beijing, China
Site recruitment: Not reported
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, China
Site recruitment: Not reported
The Second Affiliated Hospital of Nanchang University
Nanchang, China
Site recruitment: Not reported
Shanghai East Hospital Tongji University
Shanghai, China
Site recruitment: Not reported
TEDA International Cardiovascular Hospital
Tianjin, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

ClinicalTrials.gov · NCT06139419 · Registry updated: 2026-08-03

Condition / research focus: Non-small Cell Lung Cancer
Sponsor: Sun Yat-sen University
Countries with listed sites: China
Registry dates and results: Start: 2023-07-25. Completion: 2026-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

definitive radiotherapy (radiation)
induction chemo-immunotherapy (drug) — also listed as: albumin-bound paclitaxel, cisplatin, tislelizumab
concurrent chemotherapy (drug) — also listed as: albumin-bound paclitaxel, cisplatin
Immunotheapy consolidation (drug) — also listed as: tislelizumab
Thymosin Alpha1 (drug) — also listed as: thymalfasin

Where the study takes place — 1 listed sites

Sun yat-sen university cancer center
Guangzhou, Guangdong, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableEnrolling by invitationINTERVENTIONAL

Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI)

ClinicalTrials.gov · NCT06966687 · Registry updated: 2026-01-14

Condition / research focus: Aortic Dissection; Aortic Dissection Aneurysm
Sponsor: Nanjing Medical University
Countries with listed sites: China
Registry dates and results: Start: 2025-04-01. Completion: 2026-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ulinastatin and Thymosin α1 (drug)
Ulinastatin only (drug)

Where the study takes place — 4 listed sites

Beijing Anzhen Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Site recruitment: Not reported
Shanghai East Hospital Tongji University
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
West China Hospital
Chengdu, Sichuan, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC

ClinicalTrials.gov · NCT06607926 · Registry updated: 2024-09-23

Condition / research focus: Resectable Non-Small-Cell Lung Cancer
Sponsor: Xuanwu Hospital, Beijing
Countries with listed sites: China
Registry dates and results: Start: 2024-10-15. Completion: 2025-12-30 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin Alpha 1 (drug) — also listed as: thymalfasin
Tislelizumab (drug)
Platinum-doublet chemotherapy (drug)

Where the study takes place — 1 listed sites

Xuanwu Hospital, Capital Medical University
Beijing, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Early Phase 1CompletedINTERVENTIONAL

Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder

ClinicalTrials.gov · NCT04963712 · Registry updated: 2023-07-18

Condition / research focus: HIV-1-infection
Sponsor: Shanghai Public Health Clinical Center
Countries with listed sites: China
Registry dates and results: Start: 2021-09-01. Completion: 2022-08-11 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Zadaxin (drug) — also listed as: Thymosin α1

Where the study takes place — 1 listed sites

Fudan University
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass

ClinicalTrials.gov · NCT05487469 · Registry updated: 2022-08-04

Condition / research focus: Rheumatic Heart Disease; Cardiopulmonary Bypass; Immunotherapy
Sponsor: Nanjing Medical University
Countries with listed sites: China
Registry dates and results: Start: 2022-07-01. Completion: 2023-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin Alpha1 (drug)
Blank Control (other)

Where the study takes place — 1 listed sites

The first affiliated hospital of nanjing medical university
Nanjing, Jiangsu, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer

ClinicalTrials.gov · NCT03659578 · Registry updated: 2022-01-03

Condition / research focus: Non-small Cell Lung Cancer
Sponsor: Sun Yat-sen University
Countries with listed sites: China
Registry dates and results: Start: 2018-08-09. Completion: 2021-09-30 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Concurrent chemotherapy (drug)
split-course radiotherapy (radiation)
thymosin alpha 1 (drug)

Where the study takes place — 1 listed sites

Sun yat-sen University Cancer Center
Guangzhou, Guangdong, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor

ClinicalTrials.gov · NCT03663764 · Registry updated: 2021-12-10

Condition / research focus: Thymoma and Thymic Carcinoma
Sponsor: Sun Yat-sen University
Countries with listed sites: China
Registry dates and results: Start: 2018-08-13. Completion: 2023-08 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin a1 (drug)
hypofractionated radiotherapy (radiation)
concurrent chemoradiotherapy (drug)

Where the study takes place — 1 listed sites

Sun yat-sen University Cancer Center
Guangzhou, Guangdong, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF

ClinicalTrials.gov · NCT03082885 · Registry updated: 2021-08-16

Condition / research focus: Liver Failure
Sponsor: Sun Yat-sen University
Countries with listed sites: China
Registry dates and results: Start: 2017-04-10. Completion: 2019-07-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin-α1 (drug) — also listed as: Zadaxin

Where the study takes place — 1 listed sites

Third Affliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableNot yet recruitingOBSERVATIONAL

Long-term Prognosis of Patients With Sepsis After Immunotherapy

ClinicalTrials.gov · NCT04901104 · Registry updated: 2021-05-25

Condition / research focus: Long-term Effects of Thymosin Alpha 1 Treatment
Sponsor: Sun Yat-sen University
Countries with listed sites: No country reported
Registry dates and results: Start: 2021-07-01. Completion: 2027-03-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin Alpha1 (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3UnknownINTERVENTIONAL

Thymosin-α1 in Cancer-Related Fatigue

ClinicalTrials.gov · NCT02127268 · Registry updated: 2019-04-10

Condition / research focus: Cancer Related Fatigue; Quality of Life
Sponsor: Zhigang Zhang
Countries with listed sites: China
Registry dates and results: Start: 2014-04. Completion: 2020-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin-α1 (drug)

Where the study takes place — 1 listed sites

Cancer institute
Hangzhou, Zhejiang, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

The Curative Effect of Entecavir Combined Resveratrol on HBV patients-a Multi-center, Random, Open Clinical Trial

ClinicalTrials.gov · NCT03509688 · Registry updated: 2018-04-26

Condition / research focus: Hepatitis
Sponsor: The First Hospital of Jilin University
Countries with listed sites: No country reported
Registry dates and results: Start: 2014-11. Completion: 2017-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

entecavir+resveratrol (drug)
Entecavir (drug)
entecavir+thymosin α1 (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →